---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000999"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T04:51:10.785204+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Charles River Q2 revenue $973.1M (+6.4% YoY); non-GAAP EPS $2.77 (+6.1%); cuts FY22 guidance

## Summary
- GAAP EPS $2.13 vs $1.72 Q2 2021; non-GAAP EPS $2.77 vs $2.61.
- Revenue $973.1M, organic growth 9.5% led by DSA and RMS segments.
- FY22 guidance cut: organic rev growth 10-12% (prev 12.5-14.5%), non-GAAP EPS $10.70-$10.95 (prev $11.50-$11.75).
- DSA segment revenue $591.9M (+12.9% organic); operating margin improved to 25.3% non-GAAP.
- Manufacturing segment revenue $194.8M (-1.5%); CDMO weakness offset by Biologics Testing growth.

## SEC filing metadata
- accession: 0001157523-22-000999
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000115752322000999/0001157523-22-000999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000115752322000999/a52799763.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000999
- JSON: https://secwatch.observer/filing/0001157523-22-000999.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.